Prolonged use of the following drug has been implicated in the causation of subacute myelo–optic neuropathy (SMON) :
**Core Concept**
Subacute myelo–optic neuropathy (SMON) is a rare but serious condition characterized by progressive damage to the spinal cord and optic nerve. This condition has been associated with prolonged use of certain medications that have toxic effects on the nervous system.
**Why the Correct Answer is Right**
The correct answer is Clofibrate, a fibric acid derivative used to lower cholesterol and triglyceride levels in the blood. Prolonged use of Clofibrate has been implicated in the causation of SMON due to its toxic effects on the nervous system, particularly the spinal cord and optic nerve. The exact mechanism is not fully understood, but it is thought to involve the accumulation of toxic metabolites that damage the nervous tissue.
**Why Each Wrong Option is Incorrect**
**Option A:** Cholestyramine is a bile acid sequestrant used to lower cholesterol levels, but it has not been associated with SMON. It works by binding to bile acids in the gut and preventing their reabsorption, which leads to increased excretion of bile acids.
**Option B:** Gemfibrozil is another fibric acid derivative used to lower triglyceride levels, but it has not been linked to SMON. While it has similar mechanisms of action to Clofibrate, its toxicity profile is different, and it is not associated with this rare condition.
**Option C:** Niacin (Vitamin B3) is a water-soluble vitamin that has been used to lower cholesterol and triglyceride levels. It has not been associated with SMON, and its use is generally considered safe when used in recommended doses.
**Clinical Pearl / High-Yield Fact**
To remember the association between Clofibrate and SMON, recall the acronym **CLOFIBRATE**, where each letter stands for a key detail: C (Cholesterol), L (Lowering), O (Optic nerve damage), F (Fibric acid derivative), I (Increased risk of SMON), B (Bile acid sequestration not involved), R (Rare but serious condition), A (Associated with Clofibrate use), T (Toxic metabolites implicated), E (Exposure to Clofibrate increases risk).
**Correct Answer: A. Clofibrate**